Intranasal administration of antiretroviral-loaded micelles for anatomical targeting to the brain in HIV

Nanomedicine

Volumn 8, Issue 2, 2013, Pages 223-237

  Chiappetta, Diego A ^a,b   Hocht, Christian ^a   Opezzo, Javier A W ^a   Sosnik, Alejandro ^a,b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

anatomical targeting to the brain; CNS; efavirenz loaded micelles; HIV reservoirs; intranasal administration

Indexed keywords

COPOLYMER; EFAVIRENZ; MACROGOL; POLOXAMER; POLOXAMINE 908; POLY(PROPYLENE OXIDE); POLYMER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; CHEMICAL COMPOSITION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG STABILITY; DRUG TARGETING; HUMAN IMMUNODEFICIENCY VIRUS; HYDROPHILICITY; MALE; MAXIMUM PLASMA CONCENTRATION; MICELLE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SCANNING ELECTRON MICROSCOPY;

EID: 84873572080     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.12.104     Document Type: Article

References (79)

1. Gazzard BG, Jones RS. From death to life: two decades of progress in HIV therapy. In: HIV/AIDS in Europe: Moving from Death Sentence to Chronic Disease Management. Matic S, Lazarus JV, Donoghoe MC (Eds). WHO Regional Office for Europe Publications, Copenhagen, Denmark, 101-117 (2006).
2. De Clercq E. Antiretroviral drugs. Curr. Opin. Pharmacol. 10, 507-515 (2010).
3. Romanelli F, Hoven AD. Use of virostatics as a means of targeting human immunodeficiency virus infection. Curr. Pharm. Des. 12, 1121-1117 (2006).
4. Park S, Sinko P. P-glycoprotein and multidrug resistance-associated proteins limit the brain uptake of saquinavir in mice. J. Pharmacol. Exp. Ther. 312, 1249-1256 (2005).
5. Geeraert L, Kraus G, Pomerantz RJ. Hide-and-seek: the challenge of viral persistence in HIV infection. Ann. Rev. Med. 59, 487-501 (2008).
6. Padowski JM, Pollack GM. Examination of the ability of the nasal administration route to confer a brain exposure advantage for three chemical inhibitors of P-glycoprotein. J. Pharm. Sci. 99, 3226-3233 (2010).
7. Csajka C, Marzollini C, Fattinger K et al. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin. Pharm. Ther. 73, 20-30 (2003).
8. Aarnoutse R, Schapiro JM, Bouchr CAB, Hkster YA, Burger DM. Therapeutic drug monitoring. Drugs 63, 741-753 (2003).
9. Aungst BJ. P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugs. Adv. Drug Del. Rev. 39, 105-116 (1999).
10. Balimane PV, Sinko PJ. Involvement of multiple transporters in the oral absorption of nucleoside analogues. Adv. Drug Del. Rev. 39, 183-209 (1999).
11. Shaik N, Giri N, Pan G, Elmquist WF. P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution. Drug Metabol. Dispos. 35, 2076-2085 (2007).
12. Ronaldson PT, Persidsky Y, Bendayan R. Regulation of ABC membrane transporters in glial cells: relevance to the pharmacotherapy of brain HIV-1 infection. Glia 56, 1711-1735 (2008).
13. Vivithanaporn P, Gill MJ, Power C. Impact of current antiretroviral therapies on neuroAIDS. Expert Rev. Anti Infect. Ther. 9, 371-374 (2011).
14. Nath A, Sacktor N. Influence of highly active antiretroviral therapy on persistence of HIV in the central nervous system. Curr. Opin. Neurol. 19, 358-361 (2006).
15. Crews L, Patrick C, Achim CL, Everall IP, Masliah E. Molecular pathology of neuro-AIDS (CNS-HIV). Int. J. Mol. Sci. 10, 1045-1063 (2009).
16. Dash PK, Gorantla S, Gendelman HE et al. Loss of neuronal integrity during progressive HIV-1 infection of humanized mice. J. Neurosci. 31, 3148-3157 (2011).
17. Grovit-Ferbas K, Harris-White ME. Thinking about HIV: the intersection of virus, neuroinflammation and cognitive dysfunction. Immunol. Res. 48, 40-58 (2010).
18. Van Rie A, Mupuala A, Dow A. Impact of the HIV/AIDS epidemic on the neurodevelopment of preschool-aged children in Kinshasa, Democratic Republic of the Congo. Pediatrics 122, E123-E128 (2008).
19. Cook-Easterwood J, Middaugh LD, Griffin WC 3rd, Khan I, Tyor WR. Highly active antiretroviral therapy of cognitive dysfunction and neuronal abnormalities in SCID mice with HIV encephalitis. Exp. Neurol. 205, 506-512 (2007).
20. Sosnik A, Chiappetta DA, Carcaboso A. Drug delivery systems in HIV pharmacotherapy: what has been done and the challenges standing ahead. J. Control. Release 138, 2-15 (2009).
21. Wong HL, Chattopadhyay N, Wu XY, Bendayan R. Nanotechnology applications for improved delivery of antiretroviral drugs to the brain. Adv. Drug Del. Rev. 62, 503-517 (2010).
22. Kuo Y-Ch, Su FL. Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate- sulfopropylmethacrylate, and solid lipid nanoparticles. Int. J. Pharm. 340, 143-152 (2007).
23. Kuo Y-Ch, Kuo Ch-Y. Electromagnetic interference in the permeability of saquinavir across the blood-brain barrier using nanoparticulate carriers. Int. J. Pharm. 351, 271-281 (2008).
24. Chattopadhyay N, Zastre J, Wong HL, Wu XY, Bendayan R. Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line. Pharm. Res. 25, 2262-2271 (2008).
25. Mishra V, Mahor S, Rawat A et al. Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles. J. Drug Target. 14, 45-53 (2006).
26. Shaik N, Pan G, Elmquist WF. Interactions of pluronic block copolymers on P-gp efflux activity: Experience with HIV-1 protease inhibitors. J. Pharm. Sci. 97, 5421-5433 (2008).
27. Shaik N, Giri N, Elmquist WF. Investigation of the micellar effect of Pluronic P85 on P-glycoprotein inhibition: cell accumulation and equilibrium dialysis studies. J. Pharm. Sci. 98, 4170-4190 (2009).
28. Nowacek A, Gendelman HE. NanoART, neuroAIDS and CNS drug delivery. Nanomedicine (Lond.) 4, 557-574 (2009).
29. Sosnik A, Amiji M. Nanotechnology solutions for infectious diseases in developing nations. Adv. Drug Del. Rev. 62, 375-377 (2010).
30. Sosnik A. Nanotechnology contributions to the pharmacotherapy of pediatric HIV: A dual scientific and ethical challenge and a still pending agenda. Nanomedicine (Lond.) 5, 833-837 (2010).
31. Sosnik A, Carcaboso AM, Chiappetta DA. Polymeric nanocarriers: new endeavors for the optimization of the technological aspects of drugs. Recent Pat. Biomed. Eng. 1, 43-59 (2008).
32. Chiappetta DA, Sosnik A. Poly(ethylene oxide)-poly(propylene oxide) block copolymer micelles as drug delivery agents: improved hydrosolubility, stability and bioavailability of drugs. Eur. J. Pharm. Biopharm. 66, 303-317 (2007).
33. Sosnik A, Sefton MV. Semi-synthetic collagen/poloxamine matrices for tissue engineering. Biomaterials 26, 7425-7435 (2005).
34. Sosnik A, Leung B, McGuigan AP, Sefton MV. Collagen/poloxamine hydrogels: Cytocompatibility of embedded HepG2 cells and surface attached endothelial cells. Tissue Eng. 11, 1807-1816 (2005).
35. Kurkalli BGS, Gurevitch O, Sosnik A, Cohn D, Slavin S. Repair of bone defect using bone marrow cells and demineralized bone matrix supplemented with polymeric materials. Curr. Stem Cell Res. Ther. 5, 49-56 (2010).
36. Fabbiani M, Di Giambenedetto S, Bracciale L et al. Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice. J. Antimicrob. Chemother. 64, 109-117 (2009).
37. Smith PF, Robbins GK, Shafer RW et al. Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 49, 3558-3561 (2005).
38. Marzolini C, Telenti A, Decosterd L, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15, 1193-1194 (2001).
39. López-Cortés LF, Ruiz-Valderas R, Marín-Niebla A et al. Therapeutic drug monitoring of efavirenz: trough levels cannot be estimated on the basis of earlier plasma determinations. J. Acquir. Immune Defic. Syndr. 39, 551-556 (2005).
40. Peroni RN, Di Gennaro SS, Hocht C et al. Efavirenz is a substrate and in turn modulates the expression of the efflux transporter ABCG2/BCRP in the gastrointestinal tract of the rat. Biochem. Pharmacol. 82, 1227-1233 (2011).
41. Peroni RN, Hocht C, Chiappetta DA et al. The anti-HIV drug efavirenz is substrate and modulates the expression of the efflux transporter BCRP (ABCG2) in rats. Presented at: First World Conference on Nanomedicine and Drug Delivery (WCN2010). Kottayam, India, 16-18 April 2010.
42. Dutta T, Agashe HB, Garg M, Balasubramanium P, Kabra M, Jain NK. Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro. J. Drug Target 15, 89-98 (2007).
43. Destache CJ, Belgum T, Goede M, Shibata A, Belshan MA. Antiretroviral release from poly(dl-lactide-co-glycolide) nanoparticles in mice. J. Antimicrob. Chemother. 65, 2183-2187 (2010).
44. Nowacek AS, Balkundi S, McMillan J et al. Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. J. Control. Release 150, 204-211 (2011).
45. Chiappetta DA, Hocht C, Taira C, Sosnik A. Efavirenz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral bioavailaibility. Nanomedicine (Lond.) 5, 11-23 (2010).
46. Chiappetta DA, Hocht C, Taira C, Sosnik A. Oral pharmacokinetics of the anti- HIV efavirenz encapsulated within polymeric micelles. Biomaterials 32, 2379-2387 (2011).
47. Chiappetta DA, Alvarez-Lorenzo C, Rey-Rico A, Taboada P, Concheiro A, Sosnik A. N-alkylation of poloxamines modulates micellar encapsulation and release of the antiretroviral efavirenz. Eur. J. Pharm. Biopharm. 76, 24-37 (2010).
48. Chiappetta DA, Facorro G, Rubin de Celis E, Sosnik A. Synergistic encapsulation of the anti-HIV agent efavirenz within poly(ethylene oxide)-poly(propylene oxide) mixed polymeric micelles. Nanomedicine 7, 624-637 (2011).
49. Chiappetta DA, Hocht C, Sosnik A. A highly concentrated and taste-improved aqueous formulation of efavirenz for a more appropriate paediatric management of the anti-HIV therapy. Curr. HIV Res. 8, 23-31 (2010).
50. Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int. J. Pharm. 379, 146-157 (2009).
51. Dhuria SV, Hanson LR, Frey WH 2nd. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J. Pharm. Sci. 99, 1654-1673 (2010).
52. Kanazawa T, Taki H, Tanaka K, Takashima Y, Okada H. Cell-penetrating peptide-modified block copolymer micelles promote direct brain delivery via intranasal administration. Pharm. Res. 28, 2130-2139 (2011).
53. Cheng Q, Feng J, Chen J, Zhu X, Li F. Brain transport of neurotoxin-I with PLA nanoparticles through intranasal administration in rats: A microdialysis study. Biopharm. Drug Dispos. 29, 431-439 (2008).
54. Mainardes RM, Khalil NM, Gremião MP. Intranasal delivery of zidovudine by PLA and PLA-PEG blend nanoparticles. Int. J. Pharm. 95, 266-271 (2010).
55. Al-Ghananeem AM, Saeed H, Florence R, Yokel RA, Malkawi AH. Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by AIDS viruses. J. Drug Target 18, 381-388 (2010).
56. Jain R, Nabar S, Dandekar P et al. Formulation and evaluation of novel micellar nanocarrier for nasal delivery of sumatriptan. Nanomedicine (Lond.) 5, 575-587 (2010).
57. Illum L. Is nose-to-brain transport of drugs in man a reality? J. Pharm. Pharmacol. 56, 3-17 (2004).
58. Ribeiro A, Sosnik A, Chiappetta DA, Veiga F, Concheiro A, Alvarez-Lorenzo C. Single and mixed poloxamine micelles as suitable nanocarriers for solubilization and sustained release of ethoxzolamide for topical glaucoma therapy. J. Royal Soc.-Interface 9, 2059-2069 (2012).
59. Höcht C, Opezzo JA, Taira CA. Microdialysis in drug discovery. Curr. Drug Discov. Technol. 1, 269-285 (2004).
60. Höcht C, Lazarowski A, Gonzalez NN et al. Nimodipine restores the altered hippocampal phenytoin pharmacokinetics in a refractory epileptic model. Neurosci. Lett. 413, 168-172 (2007).
61. Maurin MB, Rowe SM, Blom K et al. Kinetics and mechanism of hydrolysis of efavirenz. Pharm. Res. 19, 517-521 (2002).
62. Rao KS, Reddy MK, Horning JL, Labhasetwar V. TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials 29, 4429-4438 (2008).
63. Prinsen BH, de Sain-van der Velden MG. Albumin turnover: experimental approach and its application in health and renal diseases. Clin. Chim. Acta 347, 1-14 (2004).
64. Liu J, Zeng F, Allen C. Influence of serum protein on polycarbonate-based copolymer micelles as a delivery system for a hydrophobic anti-cancer agent. J. Control. Release 103, 481-497 (2005).
65. Lo CL, Huang CK, Lin KM, Hsiue GH. Mixed micelles formed from graft and diblock copolymers for application in intracellular drug delivery. Biomaterials 28, 1225-1235 (2007).
66. Kabanov AV, Nazarova IR, Astafieva IV et al. Micelle formation and solubilization of fluorescent probes in poly(oxyethylene-b-oxypropylene-b- oxyethylene) solutions. Macromolecules 28, 2303-2314 (1995).
67. Southam DS, Dolovich M, O'Byrne PM, Inman MD. Distribution of intranasal instillations in mice: effects of volume, time, body position, and anestesia. Am. J. Physiol. Lung Cell Mol. Physiol. 282, L833-L839 (2002).
68. van Rooy I, Cakir-Tascioglu S, Hennink WE, Storm G, Schiffelers RM, Mastrobattista E. In vivo methods to study uptake of nanoparticles into the brain. Pharm. Res. 28, 456-471 (2011).
69. de Lange EC, de Boer BA, Breimer DD. Microdialysis for pharmacokinetic analysis of drug transport to the brain. Adv. Drug Deliv. Rev. 36, 211-227 (1999).
70. Gaucher G, Satturwar P, Jones MC, Furtos A, Leroux JC. Polymeric micelles for oral drug delivery. Eur. J. Pharm. Biopharm. 76, 147-158 (2010).
71. Balani SK, Kauffman LR, deLuna FA, Lin JH. Non-linear pharmacokinetics of efavirenz (DMP-266), a potent HIV-1 reverse transcriptase inhibitor, in rats and monkeys. Drug Metabol. Disp. 27, 141-145 (1999).
72. Wohlfart S, Gelperina S, Kreuter J. Transport of drugs across the blood-brain barrier by nanoparticles. J. Control. Release 161(2), 264-273 (2012).
73. Petri B, Bootz A, Khalansky A et al. Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants. J. Control. Release 117, 51-58 (2007).
74. Alvarez-Lorenzo C, Rey-Rico A, Brea J, Loza MI, Concheiro A, Sosnik A. Inhibition of P-glycoprotein pumps by PEO-PPO amphiphiles: branched versus linear derivatives. Nanomedicine (Lond.) 5, 1371-1383 (2010).
75. Cuestas ML, Sosnik A, Mathet VL. Poloxamines display a multiple inhibitory activity of ATP-binding cassette (ABC) transporters in cancer cell lines. Mol. Pharmaceutics 8, 1152-1164 (2011).
76. Cuestas ML, Castillo A, Sosnik A, Mathet VL. Downregulation of mdr1 and abcg2 genes is a mechanism of inhibition of efflux pumps mediated by polymeric amphiphiles. Bioorg. Med. Chem. Lett. 22, 6577-6579 (2012).
77. Lourenço Cardoso F, Brites D, Brito MA. Looking at the blood-brain barrier: molecular anatomy and possible investigation approaches. Brain Res. Rev. 64, 328-363 (2010).
78. Dhanda D, Frey WH 2nd, Leopold D, Kompella UB. Approaches for drug deposition in the human olfactory epithelium. Drug Deliv. Technol. 5, 64-72 (2005).
79. Zhang QZ, Zha LS, Zhang Y et al. The brain targeting efficiency following nasally applied MPEG-PLA nanoparticles in rats. J. Drug Target 14, 281-290 (2006).